AJMC® in the Press, July 12, 2019

An article appearing in The New York Times cited a study published in The American Journal of Managed Care^® (AJMC^®). Researchers of the study, “Improving Provider Directory Accuracy: Can Machine-Readable Directories Help?,” examined the accuracy of provider directories and found widespread errors, leading them to conclude that machine-readable directories are not more accurate than conventional directories, despite their advantages. The study was also highlighted by Becker’s Hospital Review.

A Forbes article on biosimilars referred to an article from AJMC^®’s sister site The Center for Biosimilars^®. The article, “Biologics Are Not Monopolies to Be Regulated, AEI Economists Assert,” covered a blog post by 2 economists from the American Enterprise Institute in which they shot back at the idea that biosimilars are natural monopolies and should have their prices regulated by the government, which was proposed by critics a few months prior.

The Health Affairs blog referenced an AJMC^® published study from May. The study, "Producing Comparable Cost and Quality Results From All-Payer Claims Databases," described a replicable process for standardizing disparate databases and methods to calculate cost and quality measures within and across states.

The AJMC^® published study “Pharmacogenetic-Guided Psychiatric Intervention Associated With Increased Adherence and Cost Savings” was cited in an article from The Doctor Weighs In. According to the 2014 study, the data show the utility of pharmacogenetic testing in everyday psychiatric clinical practice, as it can lead to improved patient adherence and decreased healthcare costs.

The National Pharmaceutical Council’s Tuesday CER Daily Newsfeed included AJMC^®’s article “Despite Growth, Uptake of Downside Risk in ACO Contracts Remains Low,” which covered a study that found in 2018, 33% of accountable care organizations assumed downside risk, up from 28% in 2012.